Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
COPD
At GSK, our Ellipta portfolio delivers an effective and simple approach to COPD treatment, whilst our Ellipta device is the only once-daily inhaler that enables device continuity for patients with COPD.
COPD resources
As well as our Ellipta portfolio of COPD treatments, we are also committed to improving patient outcomes through the resources we offer. Our Ellipta demonstration device can help you demonstrate correct use of the Ellipta inhaler to your patients.
IMPORTANT: The Ellipta demonstration device is intended for demonstration only and not for patient use. Patients should not inhale from the demonstration device.
References:
- Trelegy SmPC, available at www.medicines.ie
- Anoro Ellipta SmPC, available at www.medicines.ie
- Incruse SmPC, available on www.medicines.ie
- van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079
Developed in association with INNOVIVA.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1 80 0 2 442 5 5.
© 2024 GlaxoSmithKline Group of Companies. Anoro, Incruse, Trelegy and Ellipta are trademarks of the GSK group of companies.
